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Background. Microarray-based, multiplexed, automated molecular method is a rapid diagnosis of bloodstream infections by directly identify bacterial pathogens and antibiotic resistance by detection resistance genes from positive blood culture. Previous studies showed significantly reduce time to organism identification from positive blood culture and antibiotic resistance gene with 97.1% sensitivity and 100% specificity. This study aimed to evaluate time to appropriate antibiotic between using Microarray Assay and Mass Spectrometry technique for bacterial identification.
Methods. one hundred and forty-five patients with bloodstream infection in medical ward were enrolled between 1 June 2018 and 31 January 2019. There were 2 study periods (pre-intervention and post-intervention), using MALDI-TOF combined with the conventional microbiological method as the current standard diagnostic method in pre-intervention group (N = 70) and microarray technique was used add-on to post-intervention group (N = 75). Antibiotic therapy was adjusted by infectious disease team in both periods of study.
Results. There were significantly faster bacterial identification and detection of antibiotic resistance (39.34 hours vs. 5 hours, P = 0.0001) as well as time to adjust specific antibiotic therapy (75 hours vs. 27.65 hours, P = 0.0001) resulted in earlier appropriate antibiotic therapy (31 hours vs. 0 hours, P = 0.005) and decrease unnecessary of antibiotic adjustment (51.4% vs. 37.3%). However, allcause mortality within 2 weeks was not significantly reduced (11.4% vs. 14.7%), no differences cost of antibiotic therapy and length of hospital stay (13 days vs. 17 days).
Conclusion. Microarray technique has rapid turnaround time to bacterial identification and detection of some resistant genes. A combination of this technique and clinical judgement encourage earlier appropriateness antibiotic therapy and may be helpful in antibiotic stewardship program.
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No reported disclosures. Background. Group A Streptococcus (GAS), is currently diagnosed by throat culture or rapid antigen detection test (RADT) by a healthcare provider (HP), usually in an outpatient (OP) setting. There is current interest in expanding OTC diagnostics (FDA approved for HIV and hepatitis C) to other infectious diseases such as GAS pharyngitis. There are no data on parental acceptance of such a test. Our aim was to determine parental acceptance of expanding OTC diagnostic availability for GAS pharyngitis testing.
Parental Acceptance of
Methods. Caregivers of 3-18 years old in OP primary care pediatric clinics were given a questionnaire: data included demographics (excluding all patient identifiers), interest in buying/using an OTC GAS test, education level, type of health insurance (HI), comfort level swabbing their child, interest in available support/free hotline with the test. Statistical analysis included Mann-Whitney U test for non-continuous and T-test for continuous variables.
Results. 90 questionnaires were collected, 14 duplicates excluded. 34 (45%) parents indicated they would buy an OTC GAS test, 35 (46%) would not, 4 (5%) were unsure, 3 (4%) did not respond. There was no correlation between interest in OTC test and age (P = NS), or education level (P = NS). There was a trend of OTC test interest among those with private HI vs. Medicaid (P = 0.067). There was a statistically significant association between interest in buying an OTC GAS test and the following variables: high self-swab comfort level and availability of support (P = 0.009 and 0.001, respectively). The majority of participants [73/76 (96%)] did not respond to questions about acceptable pricing.
Conclusion. There was mixed interest in OTC GAS testing among respondents. Neither age nor educational level affected interest. Surprisingly, 96% of respondents declined to select a price they would pay for an OTC GAS test. Greater interest in OTC GAS testing among respondents with private HI suggests those parents are more likely to purchase the kits to avoid an HP visit (and co-payment). Since most respondents were comfortable self-swabbing or unsure, further education including swab tutorial and support availability may lead to greater comfort level with such testing.
Disclosures. All authors: No reported disclosures. Saturday, October 5, 2019: 12:15 PM Background. Murine typhus is an arthropod borne disease of worldwide distribution with recent reemergence in the United States of America. There is limited data about the presentation, treatment and outcomes in the pregnant population. We report two cases of murine typhus in pregnancy, as well as a case series based in literature published between 1990 and 2019.
Murine Typhus and
Methods. A comprehensive search in Pubmed database using words murine typhus, pregnancy, R. typhi and endemic typhus was done. Exclusion criteria were asymptomatic murine typhus in pregnancy and undiagnosed febrile illness in pregnancy.
Results. Six articles met the criteria of symptomatic pregnant murine typhus infection. Four case reports plus our own 2 case reports, and 2 observational population studies. A total of 35 pregnancy patients were identified. Distribution was worldwide. Gestational age at presentation varied. Patients frequently presented with prolonged duration of fevers prior to presentation, headache, rash, thrombocytopenia and elevated hepatic transaminases. Diagnosis was mainly based on serology. Treatment varied and 8 cases did not receive any treatment at all. Overall pregnancy outcome
